Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 310.00
Bid: 309.00
Ask: 310.00
Change: 10.00 (3.33%)
Spread: 1.00 (0.324%)
Open: 304.00
High: 316.00
Low: 304.00
Prev. Close: 300.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Pantheon up on resource upgrade, farmout talks

Fri, 16th Jul 2021 11:19

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

----------

AIM - WINNERS

----------

Pantheon Resources PLC, up 17% at 60.64 pence, 12-month range 17p-63.40p. The oil & gas exploration and development company completes its internal analysis of the SMD-B sequence encountered in the Talitha #A well, located on the Alaska North Slope. The SMD is the shallowest of five discrete oil bearing intervals encountered in that well. The data obtained in Talitha #A has allowed Pantheon to integrate well log response and core data with seismic petrophysics to more accurately map this interval. Pantheon says analysis of the SMD-B zone is estimated to show that this zone has the potential to contain 2.6 billion barrels oil in place and a P50 contingent resource of 404 million barrels of recoverable oil. This compares to 1.8 billion barrels of oil in place and 484 million barrels of contingent resource across all three zones previously. Pantheon also said it is in discussions for farmouts of a percentage of one or more Alaskan projects.

----------

ImmuPharma PLC, up 6.4% at 8.77p, 12-month range 7.63p-17.10p. The biopharmaceutical company names Tim Franklin as chief operating officer. Franklin has worked with ImmuPharma for over three years, initially as a consultant. His key responsibilities include working closely with ImmuPharma's clinical team and scientific advisors, as the company looks to further progress its wider drug development portfolio, both through clinical development and partnering opportunities.

----------

Hutchmed (China) Ltd, up 5.2% at 572.00p, 12-month range 337p-656p. The biopharmaceutical company says the European Medicines Agency has passed its marketing authorization application for surufatinib, a treatment for pancreatic and extra-pancreatic neuroendocrine tumours. Adds the agency's validation confirms that the submission is ready for formal review.

----------

SigmaRoc, up 3.3% at 92.41p, 12-month range 37.20p-101p. The building materials company raises GBP260 million, before expenses, via the issue of 305.9 million new shares at a price of 85 pence each. The gross proceeds from the placing will be used to satisfy the EUR270 million cash element of the EUR470 million due pursuant to the acquisition of Nordkalk. Meanwhile, the retail offer has raised additional gross proceeds of GBP1.6 million at the placing price for the company, via the subscription for 1.9 million new shares, which will be used for general working capital purposes.

----------

AIM - LOSERS

----------

eve Sleep PLC, down 16% at 3.88p, 12-month range 1.30p-9.50p. The direct-to-consumer mattress retailer says UK & Ireland market had "good" first half. Expects group revenue in six months to June 30 of GBP13.9 million, up 13% year on year. UK & Ireland revenue surged 18%, but notes French revenue down 8%, attributed to "minimal" marketing investment in the first quarter ahead of a new TV campaign, which was launched in May. Notes that versus pre-pandemic revenue in the first half of 2019, UK & Ireland sales were 15% higher.

----------

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
26 Apr 2024 16:09

Hutchmed notes CHMP's positive opinion for fruiquintinib approval

(Alliance News) - Hutchmed (China) Ltd on Friday said that its partner Takeda Pharmaceutical Co Ltd has been notified that the Committee for Medicinal Products for Human Use of the European Medicines Agency recommends approval for fruquintinib.

Read more
5 Apr 2024 11:54

Hutchmed China to make several presentations at cancer research meeting

(Sharecast News) - Hutchmed China announced the upcoming presentation of new and updated data from various studies featuring compounds it had discovered on Friday, at the American Association of Cancer Research (AACR) annual meeting from 5 to 10 April in San Diego, California.

Read more
2 Apr 2024 12:11

Hutchmed endometrial cancer treatment gets priority review in China

(Sharecast News) - Hutchmed China announced the acceptance and granting of priority review by the China National Medical Products Administration (NMPA) for a new drug application combining fruquintinib and sintilimab for the treatment of advanced endometrial cancer on Tuesday.

Read more
2 Apr 2024 10:32

Hutchmed endometrial cancer treatment application accepted for review

(Alliance News) - Hutchmed (China) Ltd on Tuesday jointly announced with Innovent Biologics that their new drug application for the combined fruquintinib and sintilimab treatment for endometrial cancer has been granted priority review by the China National Medical Products Administration.

Read more
2 Apr 2024 08:05

LONDON BRIEFING: HSBC in special payout on Canada sale; Astra FDA win

(Alliance News) - London's FTSE 100 traded higher on Tuesday following the long weekend, as investors react to US data, and look ahead to manufacturing sector readings from Europe later.

Read more
28 Mar 2024 13:02

Hutchmed cancer treatment indication accepted for review in China

(Sharecast News) - Hutchmed China announced a significant milestone in its cancer treatment work on Thursday, with the supplemental new drug application (sNDA) for savolitinib had been accepted for review by the China National Medical Products Administration (NMPA).

Read more
28 Mar 2024 11:08

Hutchmed lung cancer treatment accepted for review in China

(Alliance News) - Hutchmed (China) Ltd on Thursday said its supplemental new drug application for savolitinib has been accepted for review by the China National Medical Products Administration.

Read more
28 Mar 2024 08:08

LONDON BRIEFING: JD Sports backs outlook; Spirent accepts new offer

(Alliance News) - Stocks in London traded higher early on Thursday in the final trading day of a holiday-shortened week, despite some hawkish words from a US central banker.

Read more
22 Mar 2024 10:09

Hutchmed begins registration stage for sovleplenib phase 2/3 trial

(Alliance News) - Hutchmed (China) Ltd on Friday said it initiated the registration stage of the phase 2/3 clinical trial for sovleplenib, its warm antibody autoimmune hemolytic anemia treatment.

Read more
28 Feb 2024 17:31

EARNINGS: Hutchmed revenue surges, Craven House's loss widens

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
21 Feb 2024 15:14

UK earnings, trading statements calendar - next 7 days

Thursday 22 February 
Anglo American PLCFull Year Results
Genus PLCHalf Year Results
Hargreaves Lansdown PLCHalf Year Results
Hays PLCHalf Year Results
Hikma Pharmaceuticals PLCFull Year Results
Indivior PLCFull Year Results
Jupiter Fund Management PLCFull Year Results
Lloyds Banking Group PLCFull Year Results
ME Group International PLCFull Year Results
Mondi PLCFull Year Results
Morgan Sindall Group PLCFull Year Results
Pantheon International PLCHalf Year Results
Rolls-Royce Holdings PLCFull Year Results
WPP PLCFull Year Results
Friday 23 February 
City of London Investment Group PLCHalf Year Results
Irish Residential Properties REIT PLCFull Year Results
Standard Chartered PLCFull Year Results
Monday 26 February 
Base Resources LtdHalf Year Results
Bunzl PLCFull Year Results
EnSilica PLCHalf Year Results
Kosmos Energy LtdFull Year Results
Made Tech Group PLCHalf Year Results
Tristel PLCHalf Year Results
Tuesday 27 February 
abrdn Equity Income Trust PLCFull Year Results
abrdn PLCFull Year Results
Croda International PLCFull Year Results
Kitwave Group PLCFull Year Results
McBride PLCHalf Year Results
PCI-PAL PLCHalf Year Results
Smith & Nephew PLCFull Year Results
Synectics PLCFull Year Results
Uniphar PLCFull Year Results
Unite Group PLCFull Year Results
Wednesday 28 February 
AB Dynamics PLCTrading Statement
ASA International Group PLCTrading Statement
Aston Martin Lagonda Global Holdings PLCFull Year Results
Avingtrans PLCHalf Year Results
Bluefield Solar Income Fund LtdHalf Year Results
Derwent London PLCFull Year Results
Glenveagh Properties PLCFull Year Results
Grit Real Estate Income Group LtdHalf Year Results
Hutchmed China LtdFull Year Results
International Personal Finance PLCFull Year Results
Just Eat Takeaway.com NVFull Year Results
Primary Health Properties PLCFull Year Results
Reckitt Benckiser Group PLCFull Year Results
Renewables Infrastructure Group LtdFull Year Results
RHI Magnesita NVFull Year Results
St James's Place PLCFull Year Results
Taylor Wimpey PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
7 Feb 2024 09:50

Hutchmed hails fruquintinib trial results for gastric cancer treatment

(Alliance News) - Hutchmed (China) Ltd on Wednesday said phase three data for fruquintinib in combination with paclitaxel showed an improvement in overall survival for patients with gastric or gastroesophageal junction adenocarcinoma.

Read more
2 Feb 2024 09:52

Hutchmed says Inmagene exercises option to licence drug candidates

(Alliance News) - Hutchmed (China) Ltd on Friday said Inmagene Biopharmaceuticals Ltd has exercised options to licence two drug candidates as part of a strategic partnership.

Read more
2 Feb 2024 09:42

Hutchmed partner Inmagene exercises options over two drug candidates

(Sharecast News) - Hutchmed China announced on Friday that Inmagene Biopharmaceuticals has exercised options to licence two drug candidates, IMG-007 and IMG-004, as part of their strategic partnership.

Read more
30 Jan 2024 10:32

Hutchmed's 'Elunate' approved under new Hong Kong rules

(Sharecast News) - Hutchmed China announced the approval of its drug 'Elunate', or fruquintinib, by the Pharmacy and Poisons Board of Hong Kong on Tuesday, for the treatment of adult patients with previously treated metastatic colorectal cancer (CRC).

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.